BC Extra | Nov 8, 2019
Preclinical News

Nov. 7 Preclinical Quick Takes: NIH drafts policy requiring more data sharing; plus Unum, Mission-BioLegend, DCprime and more

NIH pitches policy for greater sharing of data  NIH has published a draft of the NIH Policy for Data Management and Sharing to promote wider sharing of data and results generated from NIH-funded grant work...
BC Innovations | Oct 4, 2019
Emerging Company Profile

Arcellx debuts with $85M, tech for adapting CAR Ts

Arcellx emerged from stealth with over $85 million in series B funding and a team of CAR T veterans to develop the latest iteration of a CAR T adaptor platform that balances safety and efficacy...
BC Extra | Jul 3, 2019
Clinical News

July 3 Clinical Quick Takes: GSK starts Phase III otilimab RA program; plus Unum, Xofluza and more

Otilimab triggers milestone for MorphoSys MorphoSys AG (Xetra:MOR; NASDAQ:MOR) will receive a milestone payment of €22 million ($27.7 million) after partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) started the Phase III ContRAst program of otilimab to treat...
BC Week In Review | Dec 7, 2018
Clinical News

ASH presentations hint at future of BCMA CARs

Enhanced persistence and redirection of universal cells are among approaches companies are using to create the next generation of BCMA (tumor necrosis factor receptor superfamily member 17; TNFRSF17; CD269)-targeted CAR T cell therapies for multiple...
BC Extra | Dec 4, 2018
Clinical News

Weekend ASH presentations hint at future of BCMA CARs

Enhanced persistence and redirection of universal cells are among approaches companies are using to create the next generation of BCMA (tumor necrosis factor receptor superfamily member 17; TNFRSF17; CD269)-targeted CAR T cell therapies for multiple...
BC Week In Review | Mar 30, 2018
Financial News

Unum raises $69.2M in IPO priced at bottom of range

Unum Therapeutics Inc. (NASDAQ:UMRX) raised $69.2 million on March 28 through the sale of 5.8 million shares at $12 in an IPO underwritten by Morgan Stanley, Cowen, SunTrust Robinson Humphrey and Wedbush PacGrow. The price,...
BC Extra | Mar 29, 2018
Financial News

Unum dips after pricing IPO at bottom end of range

Unum Therapeutics Inc. (NASDAQ:UMRX) slipped $0.89 to $11.11 in its first day of trading Thursday after it raised $69.2 million through the sale of 5.8 million shares at $12 in an IPO underwritten by Morgan...
BC Week In Review | Mar 9, 2018
Financial News

Unum plans NASDAQ IPO

Immuno-oncology company Unum Therapeutics Inc. (Cambridge, Mass.) filed on March 2 to raise up to $86.3 million in an IPO on NASDAQ underwritten by Morgan Stanley, Cowen and Wedbush PacGrow. Founded in 2014, Unum is...
BC Extra | Mar 5, 2018
Financial News

Homology, Unum planning IPOs

Gene therapy and gene editing company Homology Medicines Inc. (Bedford, Mass.) and immuno-oncology company Unum Therapeutics Inc. (Cambridge, Mass.) each filed for IPOs on NASDAQ. Homology hopes to raise up to $100 million in an...
BC Week In Review | Jan 19, 2018
Clinical News

Unum reports Phase I data for ACTR087 in NHL

In November, Unum Therapeutics Inc. (Cambridge, Mass.) reported data from six evaluable patients with relapsed or refractory CD20-positive B cell non-Hodgkin's lymphoma (NHL) in the first dose cohort of the Phase I ATTCK-20-2 trial showing...
Items per page:
1 - 10 of 13